Inhaled therapies in patients with moderate COPD in clinical practice: current thinking

Znanstveni rad - Izvorni znanstveni rad

• Autor: Amnon Ariel
• Autor: Alan Altraja
• Autor: Andrey Belevskiy
• Autor: Piotr Boros
• Autor: Edvardas Danila
• Autor: Matjaz Flezar
• Autor: Vladimir Koblizek
• Autor: Zvi Gregorio Fridlender
• Autor: Kosta Kostov
• Autor: Alvils Krams
• Autor: Branislava Milenkovic
• Autor: Attila Somfay
• Autor: Ruzena Tkacova
• Autor: Neven Tudorić
• Autor: Ruxandra Ulmeanu
• Autor: Arschang Valipour
• Autorova ustanova: Sveučilište u Zagrebu; Medicinski fakultet
• Znanstveno / umjetničko područje, polje i grana: BIOMEDICINA I ZDRAVSTVO; Kliničke medicinske znanosti

Sažetak (engleski)

COPD is a complex, heterogeneous condition. Even in the early clinical stages, COPD carries a significant burden, with breathlessness frequently leading to a reduction in exercise capacity and changes that correlate with long-term patient outcomes and mortality. Implementation of an effective management strategy is required to reduce symptoms, preserve lung function, quality of life, and exercise capacity, and prevent exacerbations. However, current clinical practice frequently differs from... Više published guidelines on the management of COPD. This review focuses on the current scientific evidence and expert opinion on the management of moderate COPD: the symptoms arising from moderate airflow obstruction and the burden these symptoms impose, how physical activity can improve disease outcomes, the benefits of dual bronchodilation in COPD, and the limited evidence for the benefits of inhaled corticosteroids in this disease. We emphasize the importance of maximizing bronchodilation in COPD with inhaled dual-bronchodilator treatment, enhancing patient-related outcomes, and enabling the withdrawal of inhaled corticosteroids in COPD in well-defined patient groups. Sakrij dio sažetka

• Ključne riječi (engleski): Administration, Inhalation; Adrenal Cortex Hormones/administration & dosage; Adrenal Cortex Hormones/adverse effects; Adrenergic beta-2 Receptor Agonists/administration & dosage; Adrenergic beta-2 Receptor Agonists/adverse effects; Bronchodilator Agents/administration & dosage; Bronchodilator Agents/adverse effects; Disease Progression; Exercise Tolerance/drug effects; Health Status; Humans; Lung/drug effects; Lung/physiopathology; Muscarinic Antagonists/administration & dosage; Muscarinic Antagonists/adverse effects; Pulmonary Disease, Chronic Obstructive/diagnosis; Pulmonary Disease, Chronic Obstructive/drug therapy; Pulmonary Disease, Chronic Obstructive/physiopathology; Quality of Life; Recovery of Function; Risk Factors; Severity of Illness Index; Treatment Outcome
• Jezik: engleski
• Vrsta publikacije: Znanstveni rad - Izvorni znanstveni rad
• Status objave: Objavljen
• Vrsta recenzije: Recenziran
• Verzija publikacije: Objavljena verzija rada (izdavačev PDF)
• Naslov časopisa: International Journal of Chronic Obstructive Pulmonary Disease
• Brojčani podaci: vol. 13, str. 45-56
• p-ISSN: 1178-2005
• DOI: https://doi.org/10.2147/COPD.S145573
• URN:NBN: urn:nbn:hr:105:888485
• Datum objave publikacije: 2017-12-21
• URL dokumenta: https://doi.org/10.2147/COPD.S145573
• Vrsta resursa: Tekst
• Prava pristupa: Otvoreni pristup
• Datum i vrijeme pohrane: 2024-03-28 10:09:58